CARDIORENAL CONTINUUM, PATHOGENETICAL GROUNDS OF PREVENTIVE NEPHROLOGY
https://doi.org/10.24884/1561-6274-2005-9-3-7-15
Abstract
Cardiorenal continuum, pathogenetical grounds of preventive nephrology.
About the Authors
A. V. Smirnov
Научно исследовательский институт нефрологии, Санкт Петербургский государственный медицинский университет им. акад. И.П. Павлова
Russian Federation
Russian Federation
V. A. Dobronravov
Научно исследовательский институт нефрологии, Санкт Петербургский государственный медицинский университет им. акад. И.П. Павлова
Russian Federation
Russian Federation
I. G. Kayukov
Научно исследовательский институт нефрологии, Санкт Петербургский государственный медицинский университет им. акад. И.П. Павлова
Russian Federation
Russian Federation
References
1. Смирнов АВ, Каюков ИГ, Есаян АМ, Добронравов ВА, Кучер АГ, Тугушева ФА. Превентивный подход в современ ной нефрологии. Нефрология 2004; 8(3): 714
2. Perera GA. Hypertensive vascular disease: description and natural history. J Chron Dis 1955; 1: 3342
3. Кузьмин ОБ, Пугаева МО, Чуб СВ. Легкая дисфункция почек у больных с эссенциальной гипертонией: клиничес кие проявления и лекарственная терапия. Нефрология 2004; 8(3): 1521
4. Смирнов АВ, Есаян АМ, Каюков ИГ. Хроническая бо лезнь почек: на пути к единству представлений. Нефроло гия 2002; 6(4): 1117
5. National Kidney Foundation KD: Clinical practice guidelines for chronic kidney disease: Evaluation, classification and stratification. Am J Kidney Dis 2002; 39 [Suppl 1]: S1S266
6. Ruelope ZM, Salvetti A, Jamerson K et al. Renal function and intensive lowering of blood pressure in hypertensive participants of the hypertension optimal treatment (HOT) study. J Am Soc Nephrol 2001; 12: 218225
7. Brown MJ, Palmer CR, Castaigne A et al. Morbidity and mortality in patients randomized to doubleblind treatment with longacting calciumchannel blocker or diuretic in International Nifidipine GITS study: Intervention as a goal in Hypertension Treatment (INSIGHT). Lancet 2000: 356 (9228): 366372
8. Haroun NK, Jaar BG, Hoffman SC et al. Risk factors for chronic kidney disease: a prospective study of 23.534 men and women in Washington Country, Maryland. J Am Soc Nephrol 2003; 14: 2934 2941
9. U.S. Renal Data System. USDRS 2001. Annual Data Report, Bethesda, M.D., National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases. 2001
10. Ritz E, Dikow R, Ruilope LM. Renal dysfunction as a cardiovascular risk factor. Curr Hypertens Rep 2002; 4: 365 368
11. Смирнов АВ, Добронравов ВА, БодурОоржак АШ и др. Эпидемиология и факторы риска хронических болез ней почек: региональный уровень общей проблемы. Тер арх 2005; 77(6): 2027
12. Halimi JM, Forhan A, Balkan B et al. Is microalbuminuria an integrated risk marker for cardiovascular disease and insulin resistance in both men and women? J Cardiovasc Risk 2001; 8: 139 146
13. Orth SR. Smoking and the kidney. J Am Soc Nephrol 2002; 13: 1663 1672
14. Stuveling EM, Bakker SJ, Hilige HX et al. Biochemical risk markers: a novel area for better prediction of renal risk? Nephrol Dial Transplant 2005; 20: 497 508
15. Zavie CJ, Milani RV. Obesity and cardiovascular disease: the Hyppocrates paradox? J Am Coll Cardiol 2003; 42: 677 679
16. Kalantar Zadeh K, Block G, Horwich T, Fonarow GC. Reverse epidemiology of conventional cardiovascular risk factors in patients with chronic heart failure. J Am Coll Cardiol 2004; 48: 1439 1444
17. Stendel B, TarverCarr ME, Powe NR et al. Lifestyle factors, obesity and the risk of chronic kidney disease. Epidemiology 2003; 14: 479 487
18. Краснова ЕА, Моисеев СВ, Фомин ВВ. Нефрологи ческие аспекты проблемы ожирения. Клин мед 2005; 83 (4): 9 14
19. Kambham N, Markowitz GS, Valeri AM et al. Obesity related glomerulopathy: an emerging epidemic. Kidney Int 2001; 59: 1498 1509
20. de Jong PE, Verhave JC, Pinto Siestma SJ et al. Obesity and target organ damage: the kidney. Int J Obes Relat Metab Disord 2002; 26 [Suppl 4]: S21 S24
21. Verhave JC, Hillege HZ, Burgerhof GM et al. The association between atherosclerotic risk factors and renal function in the general population. Kidney Int 2005; 67: 1967 1973
22. Pinto Siersma SJ, Mulder J, Janssen WM et al. Smoking is related to albuminuria and abnormal renal function in nondiabetic persons. Ann Intern Med 2000; 133: 585 591
23. Klag MJ, Whelton PK, Randall BZ et al. Blood pressure and endstage renal disease in men. N Engl J Med 1996; 334: 1318
24. Fried ZF, Orchard TJ, Kasiske BZ. Effect of lipid reduction on the progression of renal disease: a metaanalysis. Kidney Int 2001; 59: 260 269
25. Schaeffner ES, Kurth T, Curhan GC et al. Cholesterol and the risk of renal dysfunction in apparently healthy men. J Am Soc Nephrol 2003; 14: 2084 2091
26. Muntner P, Coresh J, Smith JC et al. Plasma lipids and risk of developing renal dysfunction: the atherosclerosis risk in communities study. Kidney Int 2000; 58: 293 301
27. Crundy SM, Brewer HB, Cluman JI et al. Definition of metabolic syndrome: report of the National Heart, Lung and Blood Institute. American Heart Association conference on scientific issues related to definition. Circulation 2004; 109: 433 438
28. Pinto Siersma SJ, Navis G, Janssen WM et al. A central body fat distribution is related to renal function impairment, even in lean subjects. Am J Kidney Dis 2003; 41: 733741
29. Salmennienmi U, Ruotsalainen E, Philajamaki J et al. Multiple abnormalities in glucose and energy metabolism and coordinated changes in levels of adiponectin, cytokines, and adhesion molecules in subjects with metabolic syndrome. Circulation 2004; 110: 3842 3848
30. Chen J, Munter P, Hamm LZ et al. The metabolic syndrome and chronic kidney disease in US adults. Ann Intern Med 2004; 140: 167174
31. Linder A, Charka B, Sherrazd DJ, Scribner BH. Accelerated atherosclerosis in prolonged maintenance hemodialysis. N Engl J Med 1974; 290: 679 701
32. U.S. Renal Data System. USRDR 2000 Annual Data Report, Bethesda, MD, National Institute of Health, National Institute of Diabetes and Digestive and Kidney Diseases. 2000.
33. Foley RN, Parfrey PS, Sarnak MJ. Epidemiology of cardiovascular disease in chronic renal disease. J Am Soc Nephrol 1998; 9 [Suppl 12]: S16 S23
34. Смирнов АВ, Добронравов ВА, Румянцев АШ, Мнус кина ММ. Факторы риска ИБС у больных, получающих лече ние гемодиализом. Нефрология 2002; 7 [Прил 1]: 7 13.
35. Кутырина ИМ, Руденко ТЕ, Дзигоева МЮ. Ремоде лирование сосудов при хронической почечной недостаточ ности. Клин мед 2005; 2: 16 21
36. U.S. Renal Data System. USRDR 2000 Annual Data Report: Atlas of endstage renal disease in the United States. Bethseda. MD, National Institutes of Health. 2003; 1 560
37. Bongartz LG, Cramer MJ, Doevendans PA et al. The severe cardiorenal syndrome: «Guyton revisited». Eur Heart J 2005; 26: 11 17
38. Majunath G, Tighionart H, Corest F. Level of kidney function as a risk factors for cardiovascular outcomes in the elderly. Kidney Int 2003; 63: 1121 1129
39. Majunath G, Tighionart H, Ibrahim H et al. Level of Kidney function as a risk factors for atherosclerotic cardiovascular outcomes in the community. J Am Coll Cardiol 2003; 41: 47 55
40. Henry RM, Kostense PJ, Bos G et al. Mild renal insufficiency is associated with increased cardiovascular mortality: the Hoorn Study. Kidney Int 2002; 62: 1402 1407
41. Al Ahmad A, Rand WM, Manjunath G et al. Reduced kidney function and anemia as risk factors for mortality in patients with left ventricular dysfunction. J Am Coll Cardiol 2001; 38: 955 962
42. Sorensen CR, Brendorp BraskMadsen C et al. The prognostic importance of creatinine clearance after acute myocardial infarction. Eur Heart J 2002; 23: 948952
43. Anavekar NS, Me Murray JV, Velazguez EJ et al. Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. N Engl J Med 2004; 351: 13
44. Anavekar NS, Pfeffer MA. Cardiovascular risk in chronic kidney disease. Kidney Int 2004; 66 [Suppl 92]: S11 S15
45. Al Suwaidi J, Reddan DN, Williams K et al. GUSTO IIb, GUSTOIII, PURSUIT, and PARAGONA Investigators: Prognostic implications of abnormalities in renal function in patients with acute coronary syndromes. Circulation 2002; 106: 974 980
46. Gibson CM, Pinto DS, Murphy SA et al. TIMI Study Group: Association of creatinine and creatinine clearance on presentation in acute myocardial infarction with subsequent mortality. J Am Coll Cardiol 2003; 42: 1535 1543
47. Zoccali C. Cardiorenal risk as a new frontier of nephrology: research needs and areas for intervention. Nephrol Dial Transplant 2002; 17 [Suppl 11]: 50 54
48. Mourad JJ, Pannier B, Blacher J et al. Creatinine clearance, pulse wave velocity, carotid compliance and essential hypertension. Kidney Int 2001; 59: 1834 1841
49. Safar ME, Henry O, Meanme S. Aortic pulse wave velocity: an independent marker of cardiovascular risk. Am J Geriatr Cardiol 2002; 11: 295 298
50. Goldsmith D, MacGinley R, Smith A, Covic A. How important and how treatable is vascular stiffness as a cardiovascular risk factor in renal failure? Nephrol Dial Transplant 2002; 17: 965 969
51. Sarnak MJ, Cornado BE, Greene T et al. Cardiovascular disease risk factors in chronic renal insufficiency. Clin Nephrol 2002; 57: 327 335
52. Смирнов АВ. Уремическая дислипопротеинурия. Нефрология 1998; 2(1): 1521
53. Смирнов АВ, Добронравов ВА, Голубев РВ и др. Рас пространенность гипергомоцистеинемии в зависимости от стадии хронической болезни почек. Нефрология 2005; 9(2): 4852
54. Owen WF, Zowrie EG. Creactive protein as an outcome predictor for maintenance hemodialysis patients. Kidney Int 1998; 54: 627 636
55. Zimmerman J, Herrlinger S, Pruy A et al. Inflammation enhances cardiovascular risk and mortality in hemodialysis patients. Kidney Int 1999; 55: 648 658
56. Schindler R, Boenish O, Fisher C, Frei U. Effect of the hemodialysis membrane on the inflammatory reaction in vivo. Clin Nephrol 2000; 53: 452
57. Pertosa G, Gesuado Z, Boftalico D, Schena EP. Endotoxins modulate chronically tumor necrosis factor alpha and interleukin 6 release by uremia monocytes. Nephrol Dial Transplant 1995; 10: 328 333
58. Menon V, Wang X, Green T et al. Relation skip between Creactive protein, albumin, and cardiovascular disease in patients with chronic kidney disease. Am J Kidney Dis 2003; 42: 44 52
59. Friedman EA. Advanced glucation end products diabetic nephronaphy. Nephrol Dial Transplant 1999; 14 [Suppl 3]: S1
60. Zingo G, Biasucci ZM, Gallimore JR et al. The prognostic value of Creactive protein and serum amyloid a protein in severe unstable angina. N Engl J Med 1994; 331: 417 424
61. Arein M, Walls J. Endstage renal disease, atherosclerosis, and cardiovascular mortality: is Creactive protein the missing link? Kidney Int 2001; 59: 407 414
62. Zindholm B, Heimburger Q, Stenvinkel P. What are the causes of protein – energy malnutrition in chronic renal insufficiency? Am J Kidney Dis 2002; 39: 422 425
63. Ward R, Me Zeish K. Polymorphonuclear leukocyte oxidative burst is enhanced in patients with chronic renal insufficiency. J Am Soc Nephrol 1995; 5: 1697 1702
64. Steinberg D, Parthasarathy S, Carew TE et al. Beyond cholesterol. Modifications of lowdensity lipoprotein that increase its atherogenicity. N Engl J Med 1989; 320: 916 924
65. Hegarty J, Foley RN. Anaemia, renal insufficiency and cardiovascular outcome. Nephrol Dial Transplant 2001; 16 [Suppl 1]: 102 104
66. Friedman AN, Boston AG, Selhub J et al. The kidney and homocysteine metabolism. J Am Soc Nephrol 2001; 12: 2181 2189
Review
For citations:
Smirnov A.V., Dobronravov V.A., Kayukov I.G. CARDIORENAL CONTINUUM, PATHOGENETICAL GROUNDS OF PREVENTIVE NEPHROLOGY. Nephrology (Saint-Petersburg). 2005;9(3):7-15. (In Russ.) https://doi.org/10.24884/1561-6274-2005-9-3-7-15
Views:
1200
Email this article 